Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zymeworks ( (ZYME) ) has issued an announcement.
Zymeworks has received U.S. FDA Fast Track designation for ZW191, an antibody-drug conjugate targeting folate receptor-α, for patients with advanced or metastatic platinum-resistant ovarian cancer, regardless of FRα expression status. The drug is designed to internalize into FRα-expressing tumor cells and release a proprietary topoisomerase-1 inhibitor payload, building on Zymeworks’ established expertise in antibody-drug conjugate development.
The company is currently evaluating ZW191 in an ongoing Phase 1 trial in advanced solid tumors to assess safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will guide future development strategy. Fast Track status is expected to accelerate regulatory interactions and review timelines, potentially bringing a new treatment option more quickly to patients with difficult-to-treat cancers and reinforcing Zymeworks’ positioning in the oncology ADC space.
The most recent analyst rating on (ZYME) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Overall score reflects a strong earnings-call outlook (clinical validation, regulatory path, improved FY2025 performance, and nondilutive financing) offset by weak underlying financial performance (recent losses and ongoing cash burn) and neutral technicals; valuation remains challenged due to unprofitability (negative P/E).
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disorders. Its asset and royalty aggregation strategy centers on licensed products such as HER2-targeted bispecific antibody Ziihera and other candidates like pasritamig, while leveraging proprietary platforms in antibody-drug conjugates and multispecific antibodies through internal development and strategic partnerships.
Average Trading Volume: 760,040
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.8B
Find detailed analytics on ZYME stock on TipRanks’ Stock Analysis page.